JNCE - ジョンス・セラピュ―ティクス (Jounce Therapeutics Inc.) ジョンス・セラピュ―ティクス

 JNCEのチャート


 JNCEの企業情報

symbol JNCE
会社名 Jounce Therapeutics Inc (ジョンス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジャウンス・セラピューティックス(Jounce Therapeutics Inc.)は臨床段階の免疫療法会社である。同社は免疫システムが腫瘍を攻撃し、患者に長続きする利益を提供する治療法を開発することにより、癌の治療法を変革することに従事する。同社は、翻訳科学プラットフォームを使用して、最初に腫瘍内の特定の細胞型に焦点を当てて標的の優先順位を付け、適切な治療法に合致するように設計された関連バイオマーカーを特定する。主要製品候補であるJTX-2011は、誘導性T細胞CO刺激薬(ICOS)に結合して活性化するモノクローナル抗体であり、第II相試験中である。   ジョンス・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、がん免疫療法の開発に従事する。免疫療法によりがん細胞を攻撃し、患者に長期にわたり効果が出る治療法を開発する。同社プラットフォ―ムによりがん細胞をタ―ゲットにし、バイオマ―カ―を特定し適切な治療を行うことを目標とする。本社所在地はマサチュ―セッツ州ケンブリッジ。   Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
本社所在地 780 Memorial Drive Cambridge MA 02139 USA
代表者氏名 Richard Murray リチャード・マレー
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 857-259-3840
設立年月日 40969
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 112人
url www.jouncetx.com
nasdaq_url https://www.nasdaq.com/symbol/jnce
adr_tso
EBITDA EBITDA(百万ドル) -31.61000
終値(lastsale) 6.415
時価総額(marketcap) 209306233.62
時価総額 時価総額(百万ドル) 182.06220
売上高 売上高(百万ドル) 61.63900
企業価値(EV) 企業価値(EV)(百万ドル) -50.64880
当期純利益 当期純利益(百万ドル) -31.15000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Jounce Therapeutics Inc revenues decreased 25% to $30.6M. Net loss applicable to common stockholders increased from $3.8M to $17.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Employee compensation R&D increase of 27% to $11.5M (expense) Stock-based Compensation in SGA increase from $839K to $2.3M (expense).

 JNCEのテクニカル分析


 JNCEのニュース

   Cubist Systematic Strategies LLC Buys 3,279 Shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE)  2021/11/29 10:00:41 Dakota Financial News
Cubist Systematic Strategies LLC raised its holdings in Jounce Therapeutics, Inc. (NASDAQ:JNCE) by 11.8% during the second quarter, Holdings Channel reports. The institutional investor owned 31,132 shares of the companys stock after buying an additional 3,279 shares during the quarter. Cubist Systematic Strategies LLCs holdings in Jounce Therapeutics were worth $212,000 as of its most []
   $31.92 Million in Sales Expected for Jounce Therapeutics, Inc. (NASDAQ:JNCE) This Quarter  2021/11/27 03:02:42 Transcript Daily
Wall Street analysts expect that Jounce Therapeutics, Inc. (NASDAQ:JNCE) will announce sales of $31.92 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Jounce Therapeutics earnings, with the lowest sales estimate coming in at $5.00 million and the highest estimate coming in at $55.75 million. Jounce Therapeutics []
   Northern Trust Corp Boosts Stock Position in Jounce Therapeutics, Inc. (NASDAQ:JNCE)  2021/11/24 09:22:41 Dakota Financial News
Northern Trust Corp lifted its stake in Jounce Therapeutics, Inc. (NASDAQ:JNCE) by 69.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 427,885 shares of the companys stock after buying an additional 175,285 shares during the quarter. Northern Trust Corp owned approximately 0.84% of Jounce []
   First Trust Advisors LP Acquires 13,103 Shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE)  2021/11/23 10:00:46 Transcript Daily
First Trust Advisors LP increased its holdings in shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE) by 21.9% during the second quarter, Holdings Channel.com reports. The fund owned 72,807 shares of the company’s stock after purchasing an additional 13,103 shares during the quarter. First Trust Advisors LP’s holdings in Jounce Therapeutics were worth $495,000 as of its […]
   Jounce Therapeutics (NASDAQ:JNCE) Upgraded to Hold by Zacks Investment Research  2021/11/23 06:48:41 Dakota Financial News
Zacks Investment Research upgraded shares of Jounce Therapeutics (NASDAQ:JNCE) from a sell rating to a hold rating in a research report sent to investors on Friday, Zacks.com reports. According to Zacks, Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Companys lead []
   Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors  2021/10/07 12:00:00 Intrado Digital Media
- Enrollment initiated in tumor-specific monotherapy and pimivalimab combination expansion cohorts
   Thinking about buying stock in BIO-key, AIM ImmunoTech, Jounce Therapeutics, Delta Air Lines, or Rekor Systems?  2021/09/21 13:31:00 Benzinga
NEW YORK , Sept. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BKYI, AIM, JNCE, DAL, and REKR. Full story available on Benzinga.com
   Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors  2021/09/15 12:00:00 Intrado Digital Media
CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors.
   : Jounce Therapeutics upgraded to outperform from market perform at Raymond James  2021/09/14 11:50:00 MarketWatch
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
   Jounce Therapeutics to Present at Upcoming Investor Conferences in September  2021/09/02 12:00:00 Intrado Digital Media
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at several upcoming investor conferences in September:
   Jounce Therapeutics to Present at Upcoming Investor Conferences in September  2021/09/02 12:00:00 Intrado Digital Media
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at several upcoming investor conferences in September:
   Jounce Therapeutics EPS beats by $0.28, beats on revenue  2021/08/05 11:10:52 Seeking Alpha
   Jounce Therapeutics Reports Second Quarter 2021 Financial Results  2021/08/05 11:00:00 Intrado Digital Media
- INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021-
   Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021  2021/07/29 12:00:00 Intrado Digital Media
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2021 financial results and provide a corporate update before market open on Thursday, August 5, 2021. Jounce Therapeutics management team will host a live conference call and webcast at 8:00am ET.
   Jounce Therapeutics: An Under The Radar And Undervalued Biotech  2021/07/13 19:44:36 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジョンス・セラピュ―ティクス JNCE Jounce Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)